+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating two experimental drugs, REGN7508 and REGN9933, in adults with Peripheral Artery Disease PAD, a condition where blood vessels in the arms and legs become narrowed. This study aims to compare these drugs to rivaroxaban and a placebo in preventing serious blood clots after Lower Extremity Revascularization LER, a procedure to improve blood flow. The trial also investigates the side effects of these drugs, their blood levels, immune responses to the drugs, and effects on blood clotting. Participants will be randomly assigned to receive REGN7508, REGN9933, rivaroxaban, or a placebo, all given according to the study protocol. The study will follow participants for up to about 42 months to observe the occurrence of major thrombotic events such as acute limb ischemia, major amputations, heart attacks, strokes, or cardiovascular death. Additional monitoring of bleeding events and immune responses to the drugs will continue for up to approximately 45 months. During the study, participants will have regular assessments including blood tests to measure drug levels and clotting function, and evaluations for any bleeding or clotting events. Researchers will track safety by monitoring adverse events and the bodys immune response to the study drugs. The long follow-up period allows detailed observation of the treatments effects and safety over time. Participants are followed until the study completion or withdrawal.

Age: 18Years +All GendersPhase 3
29 locations
A

Actively Recruiting

Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.

Age: 6Years - 17YearsAll GendersPhase 3
129 locations